HAEMOPHILUS b CONJUGATE VACCINE (HiB) (hee-mof'il-us) HibTITER, PedvaxHIB, ProHIBiT Classifications: vaccine; Therapeutic: vaccine Prototype: Hepatitis B vaccine Pregnancy Category: C |
7.5 mcg, 10 mcg, 15 mcg, 25 mcg injection
A highly purified capsular polysaccharide extracted from Haemophilus influenzae type b (Hib). Hib, principal antigen in the vaccine, promotes production of Hib anticapsular antibodies. It mediates complement-dependent bacteriolyses of H. influenzae type b organism.
The vaccine produces antibodies effective against H. influenza type b.
To provide active immunity to H. influenzae type b (Hib) infection in children 2 mo5 y.
Adults at risk of Hib infection who have Hodgkin's disease, before immunosuppressive chemotherapy.
Hypersensitivity to any component of vaccine (e.g., thiomersal); febrile illness (other than upper respiratory tract infection); active infection; immunosuppression; infants <2 mo; pregnancy (category C).
Latex hypersensitivity.
Immunoprophylaxis for H. influenzae type b Infection Child: IM 26 mo, HibTITER 0.5 mL, 3 doses 2 mo apart with booster at 15 mo; PedvaxHIB 0.5 mL, 2 doses 2 mo apart with booster at 12 mo; 711 mo, HibTITER 0.5 mL, 2 doses 2 mo apart with booster at 15 mo; PedvaxHIB 0.5 mL, 2 doses 2 mo apart with booster at 15 mo; 1214 mo, HibTITER 0.5 mL, 1 dose with booster at 15 mo; PedvaxHIB 0.5 mL, 1 dose with booster at 15 mo; 15 mo5 y, all vaccines 0.5 mL as 1 dose |
Hib polysaccharide vaccine may interfere with interpretation of antigen detection tests (e.g., latex agglutination) used in diagnosis of systemic Hib disease.
Assessment & Drug Effects
Patient & Family Education